Portal de Periódicos da CAPES

Indirect immunotargeting of CIS‐PT to human epidermoid carcinoma KB using the avidin‐biotin system

1991; Wiley; Volume: 48; Issue: 2 Linguagem: Inglês

10.1002/ijc.2910480203

1097-0215

Bilha Schechter, Ruth Arnon, Meir Wilchek, Joseph Schlessinger, Esther Hurwitz, Esther Aboud-Pirak, Michael Sela,

Biotin and Related Studies

Abstract Cis‐diamminedichloroplatinum (II) (cis‐Pt) complexed to a carboxymethyl dextran‐avidin conjugate was targeted to biotin‐monoclonal antibody 108 (b‐MAb108). This MAb recognizes the extracellular domain of the epidermal growth factor receptor (EGF‐R) on human epidermoid carcinoma (KB) cells over‐expressing EGF‐R. Cis‐Pt‐carboxymethyl‐dextran‐avidin (Pt‐dex‐Av) containing 60–90 M cis‐Pt/M avidin was administered 24 hr following b‐MAb108 containing 3–5 M biotin/ M MAb. This treatment was potentially more effective in suppressing the growth of established KB tumor xenografts, or in inhibiting the development of lung metastases in nude mice, than free MAb 108, free drug or MAb 108 followed by drug. Replacing b‐MAb108 by unbiotinylated antibody or by b‐MAb of a different specificity also yielded lower suppressive effects. The sequential administration of Pt‐dex‐Av following b‐MAb was more effective than Introduction, of the Pt‐dex‐Av when already complexed to b‐MAb 108. The results presented in this preliminary investigation suggest that Pt‐dex‐Av is specifically removed from the circulation by b‐MAb 108 concentrated at the tumor site.